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Keloids are an excessive accumulation of extracellular
matrix. Although numerous studies have shown ele-
vated plasminogen activator inhibitor-1 (PAI-1) levels
in keloid ¢broblasts compared with those of normal
skin. Their speci¢c mechanisms involved in the di¡er-
ential expression of PAI-1 in these cell types. In this
study, the upregulation of PAI-1 expression is demon-
strated in keloid tissues and their derived dermal ¢bro-
blasts, attesting to the persistence, if any, of fundamental
di¡erences between in vivo and in vitro paradigms. We
further examined the mechanisms involved in hypox-
ia-induced regulation of PAI-1 gene in dermal ¢bro-
blast derived from keloid lesions and associated
clinically normal peripheral skins from the same pa-
tient. Primary cultures were exposed to an environ-
mental hypoxia or desferroxamine. We found that the
hypoxia-induced elevation of PAI-1 gene appears to be
regulated at both transcriptional and post-transcrip-
tional levels in keloid ¢broblasts. Furthermore, our re-
sults showed a consistent elevation of HIF-1a protein
level in keloid tissues compared with their normal per-
ipheral skin controls, implying a potential role as a bio-
marker for local skin hypoxia.Treatment with antisense
oligonucleotides against hypoxia-inducible factor 1a
(HIF-1a) led to the downregulation of steady-state levels
of PAI-1 mRNA under both normoxic and hypoxic
conditions. Conceivably, our results suggest that HIF-
1a may be a novel therapeutic target to modulate the
scar ¢brosis process. Key words: hypoxia/half-life/desferrox-
amine/HIF-1a/antisense J Invest Dermatol 121:1005^1012, 2003
P
lasminogen activator inhibitor-1 (PAI-1) plays a pivotal
role in the plasminogen system that, in turn, is central
to several essential physiologic and pathologic pro-
cesses, including ¢brinolysis, extracellular matrix turn-
over, ¢brosis, wound healing, and cancer metastasis
(Andreasen et al, 1990; Eitzman et al, 1996). PAI-1 can be synthe-
sized and secreted by platelets (Erickson et al, 1985), vascular en-
dothelial cells (Reilly and McFall, 1991), vascular smooth muscle
cells (Reilly and McFall, 1991), and several nonvascular cell types
(Busso et al, 1994). PAI-1 gene expression can be regulated by a
variety of stimuli, including phorbol ester (Descheemaeker et al,
1992), transforming growth factor-b (Sawdey and Loskuto¡,
1991; Song et al, 1998), tumor necrosis factor-a (Sawdey and Los-
kuto¡, 1991), interleukin-1 (Bevilacqua et al, 1986), lipopolysac-
charide (Crutchley and Conanan, 1986; Sawdey and Loskuto¡,
1991), insulin, and insulin like growth factor-1 (Fattal et al, 1992;
Ban¢ et al, 2001), platelet-derived growth factor (Reilly and
McFall, 1991), and angiotensin II (Feener et al, 1995; Takeda et al,
2001). Recent studies reported an upregulation of PAI-1 gene ex-
pression induced by low oxygen tension (hypoxia) in trophoblast
cells (Fitzpatrick and Graham, 1998), hepatocytes (Kietzmann
et al, 1999), endothelial cells (Uchiyama et al, 2000), transformed
murine macrophages (Pinsky et al, 1998), and some cancer cell
lines (Fink et al, 2001). Furthermore, studies in cultured rat hepa-
tocytes showed that mild hypoxia (8% O2) induced PAI-1 gene
expression directly through a speci¢c promoter sequence (175/
158) that harbors hypoxia response element-1 (175/^168) and
hypoxia response element-2 (165/158), which interact with
the hypoxia-inducible factor-1 (HIF-1) (Kietzmann et al, 1999).
Fink et al (2002) have reported a tightly regulated hypoxia-re-
sponse element (194 to 187) in the promoter of the human
PAI-1 gene.
Previous studies, using a three-dimensional ¢brin gel model
system simulating ¢broplasias of wound repair, demonstrated
that keloid ¢broblasts exhibited an intrinsically high level of
PAI-1 and a low level of urokinase plasminogen activator (Tuan
et al, 1996). A marked increase in the PAI-1 transcript and protein
was also noted in ¢broblasts derived from patients with prema-
ture aging disorders (Werner’s syndrome), as well as keloid lesions
(Higgins et al, 1999). The altered ratio of activator and inhibitor
activities is a major contributing factor in both altered ¢brin de-
gradation and the subsequent extracellular matrix (ECM) meta-
bolism, leading to the formation of keloids and ¢brosis (Niessen
et al, 1999). In light of the growing evidence that the plasminogen
system plays an essential role in regulating ECM metabolism in
keloid scar formation, we examined the molecular mechanisms
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underlying the PAI-1 elevation in keloids. Conceivably, elucidat-
ing the molecular mechanisms regulating PAI-1 activity is essen-
tial for understanding the abnormal ECM metabolism and its
pathophysiologic consequences.
It has been implied by several histologic studies that a state of
local hypoxia exists in hypertrophic scars and keloids secondary
to multiple microvascular occlusions (Kischer et al, 1982; Kischer,
1992). But to date, there is still a lack of direct evidence that hy-
poxia does exist in the microenvironment of keloids. Numerous
studies in cancer cells, in vivo and in vitro, have correlated an in-
crease in HIF-1a level with a local state of tissue hypoxia (Guppy,
2002; Zagzag et al, 2002). Here, we tested the level of HIF-1a pre-
sent in fresh keloid tissues as a biomarker for skin hypoxia. Ow-
ing to the lack of a well-accepted animal model for the study of
¢brotic scar formation, we have adapted an in vitro cell system
using primary cultures of dermal ¢broblasts derived from both
the keloid center and the associated clinically normal peripheral
skin from the same patient.
We hypothesized that hypoxia-induced upregulation of the
PAI-1 gene is, at least in part, responsible for the ¢brotic pheno-
type of aberrant scars, such as keloids, by driving the steady state
of ECM metabolism to a state of excessive accumulation. To ad-
dress the mechanisms underlying the hypoxia-induced regulation
of PAI-1 gene expression in an in vitro cell system, we exposed
primary cultured dermal ¢broblasts either to a hypoxic environ-
ment (2% O2) or to desferroxamine (DFO), an iron chelator (Ha-
segawa et al, 1999) that mimics intracellular hypoxia. Using this
experimental paradigm, we observed that hypoxia-induced PAI-
1 gene expression is regulated at both the transcriptional and the
post-transcriptional levels. Our ¢ndings also support the fact that
HIF-1a plays an essential role in the hypoxia-induced upregula-
tion of PAI-1 gene expression in keloid ¢broblasts and suggest
that a novel treatment employing antisense oligonucleotides
against HIF-1amay be useful in deterring scar ¢brosis.
MATERIALS AND METHODS
Cell origin and cell culture The protocol for tissue collection was
approved by the institutional review board of the Charles R. Drew
University of Medicine and Science. Keloid tissues were taken from
patients who underwent excisional biopsies at the King Drew Medical
Center via an elliptical incision, which includes a 2- to 4-mm peripheral
rim of clinically normal skin (Table I). Clinically raised keloid lesions and
associated normal skin borders were histologically con¢rmed before
further studies (Blackburn and Cosman, 1966; Ehrlich et al, 1994). All
keloid samples obtained in this study had not been previously treated and
were not recurred cases. Using enzymatic digestion (Messadi et al, 1999),
primary dermal ¢broblasts were isolated from both keloid lesions and
from the associated clinically normal skin peripheral border of the same
patient. Fibroblast cells were cultured in Dulbecco’s modi¢ed Eagle’s
medium (Gibco, Rockville, MD) supplemented with 10% fetal bovine
serum (Gibco). All cultures were maintained at 371C, 5% CO2, and 20%
O2. Cells used for experiments were between passages 1 and 8 and were
routinely monitored for cell proliferation, morphology and phenotype.
Establishment of hypoxic culture conditions Cells growing to about
80% con£uence were transferred to a hypoxic chamber with auto purge
airlock (Coy Laboratory Products, Inc., Grass Lake, MI). Environmental
hypoxic conditions (2%) were achieved in an airtight humidi¢ed
chamber and continuously £ushed with a gas mixture containing 5%
CO2 and 95% N2. Maintenance of the desired O2 concentration was
constantly monitored during incubation using a microprocessor-based
oxygen controller (Coy Laboratory Products, Inc.). Intracellular hypoxic
conditions were generated using DFO treatment for 24 h (130 mmol/L).
Normoxic conditions were de¢ned as 20% O2, 5% CO2 at 371C.
RNA extraction and northern blot analysis Total RNA was iso-
lated from cultured cells with guanidinium thiocyanate (Chomczynski
and Sacchi, 1987). Total RNA (15 mg) was separated on a 1.4% agarose
gel containing formaldehyde and transferred onto nylon membranes
(Amersham Pharmacia Biotech UK Limited, Little Chalfont Buck-
inghamshire, UK). A cDNA fragment (262 bp) complementary to human
PAI-1 was ampli¢ed using RT-PCR, subcloned into pGEM-T Easy
Vector System (Promega, Madison,WI), labeled with [a-32P]dCTP using
the Rediprime II Random Prime DNA labeling system (Amersham
Biosciences UK Limited, Little Chalfont Buckinghamshire, UK), and
puri¢ed through Sephadex G-50 Quick Spin columns (TE; Roche
Diagnostics Corp., Indianapolis, IN). After overnight hybridization at
421C, membranes were washed and exposed to an intensifying screen in
cassette (Kodak, Rochester, NY) for 24 h and analyzed with a
phosphorimaging scanner (ImageQuant, Molecular Dynamics, Sunny-
vale, CA). Images were quanti¢ed using ImageQuant analysis software
(Molecular Dynamics).
PAI-1 mRNA stability analysis After a fresh medium change,
¢broblasts were exposed to either hypoxia or DFO for 24 h, followed by
treatment with actinomycin D (5 mg/mL, Sigma, St. Louis, MO) to inhibit
further mRNA transcription (Kietzmann et al, 1999) for a ¢xed time period
as indicated. Subsequently, cells were harvested and RNAwas prepared for
northern blot analysis as described above. Quantitation of autoradiographs
was carried out using the ImageQuant System (Molecular Dynamics) and
the level of b-actin for loading control. The relative ratios of the 3.2-kb
PAI-1 mRNA versus a-actin were graphically depicted and linear
regression analyses were performed to assess the half-life of the 3.2-kb
PAI-1 mRNA.
E¡ect of protein and RNA synthesis inhibitor on PAI-1 gene
expression Cells were pretreated with either cycloheximide (CHX, 10
mg/mL) or actinomycin D (5 mg/mL) for 1 h and then exposed to either
hypoxia or DFO for 24 h. Total RNA was isolated for northern blot
analyzes.
Western blot analyses for PAI-1 and HIF-1a proteins The tissue
homogenates were prepared as described previously (Shabsigh et al, 2001).
An equal amount (50 mg) of protein sample from each tissue homogenate
or aliquots of the conditioned medium from the cultured cells normalized
to the cell numbers were subjected to electrophoresis on 10% sodium
dodecyl sulfate^polyacrylamide gels and electroblotted onto nitrocellu-
lose membranes (Hybond ECL, Amersham Pharmacia). After blocking
with Tris-bu¡ered saline/5% skim milk, the membrane was incubated
overnight at 41C with a mouse antihuman PAI-1 antibody (American
Diagnostica Inc., Greenwich, CT) or antihuman HIF-1a monoclonal
antibody (BD Transduction Laboratory, San Jose, CA). Afterward, the
membrane was extensively washed and incubated with a horseradish
peroxidase-conjugated goat anti-mouse IgG (1:5000) (Pierce, Rockford, IL)
for 1 h at room temperature, followed by an enhanced chemiluminescent
detection (Zeheb et al, 1987).
Construction of promoter^luciferase vector and transient transfec-
tion To construct PAI-1 promoter^luciferase reporter genes, the
following forward and reverse primers were adopted to perform a PCR
using plasmid p800LUC harboring the human PAI-1 50 £anking
promoter (^800 to þ 71; gift from D.J. Loskuto¡, The Scripps Research
Table I. Tissue specimens employed in this study
Tissues Ethnicity Sex Age (years) Location Cause
Keloid lesions and its clinically normal
skin border (2- to 4-mm peripheral border)
Hispanic Male 25 Posterior ear Piercing
African American Female 28 Lateral neck Trauma
African American Male 30 Mid-chest Acne
African American Male 42 Anterior ear Piercing
African American Female 23 Posterior ear Piercing
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Institute, La Jolla, CA) as a template. The forward primer for PCR was
50 -GACAGAGCTCAAGCTTACCATGGTAACCCCT-30(^800/^779) and
the reverse primer was 50 -TCGG AGATCTCAGCTGCTGGAGGGG
GGCGT-30(þ 71/þ51), which were encompassed by the SacI (forward
primer) and BglII (reverse primer) recognition sites. PCR products were
digested, gel-puri¢ed, and subcloned into the SacI/BglII sites of the
promoterless luciferase reporter gene vector (pGL3-Basic; Promega) to
engineer the pGL3PAI-800Luc construct. Transfections of DNA into
keloid ¢broblasts were performed using SuperFect transfection reagent
(Qiagen, Valencia, CA). Cells were cotransfected with 1 mg of pGL3PAI-
800Luc and 1 mg of pRL-TKvector as an internal control for normalizing
transfection e⁄ciency. Luciferase activities under di¡erent conditions were
measured using a Dual-Luciferase reporter assay system (Promega) with a
Berthold Lumat LB9501 luminometer. Each transfection was repeated at
least three times in duplicate.
Treatment of keloid ¢broblasts with HIF-1a antisense
oligonucleotide and determination of HIF-1a and PAI-1 mRNA
by RT-PCR HIF-1a phosphorothioate antisense and sense oligonucleo-
tides were synthesized by GenoMechanix (GenoMechanix, Alachua, FL)
according to the sequences described previously (Caniggia et al, 2000);
antisense sequence, 50 -GCC GGC GCC CTC CAT-30; sense sequence, 50 -
ATG GAG GGC GCC GGC-30. Cells were washed once with serum
and antibiotic-free medium, transfected with the sense and antisense
oligonucleotides by using the Oligofectamine reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. Transfected
cells were cultured under normal conditions overnight and then exposed
to hypoxic conditions for 48 h. Total RNA was isolated from cells using
Trizol reagent (Gibco BRL). Analysis of HIF-1a, PAI-1, and b-actin
mRNA levels was performed using the one-step RT-PCR kit (Qiagen)
with primers speci¢c to HIF-1a (forward primer 50 -TCACCACA
GGACAGTACAGGATGC-30; reverse primer 50 -CCAGCAAAGTTAAA
GCATCAGGTTCC-30), PAI-1 (forward primer 50 -CGCCTCTTCCAC
AAATCAG-30, reverse primer 50 -ATGCGGGCTGAGACTATGA-30)
(Caniggia et al, 2000), and b-actin (forward primer 50 -TCATGAAGT
GTGACGTTGACATCCGT-30, reverse primer 50 -CCTAGAAGCATTTG
CGTGCACGATG-30). The PCR products were electrophoresed on 1.5%
agarose gel containing 0.5 mg per mL ethidium bromide.
RESULTS
Keloid tissues express higher levels of PAI-1 and HIF-
1a Although several studies have reported a marked increase in
PAI-1 expression in cultured primary keloid ¢broblasts compared
with that of normal skin (Tuan et al, 1996; Higgins et al, 1999),
there has been no published report, to our knowledge,
indicating that this fundamental di¡erence exists in vivo and then
persists through subsequent cultivation. In this study, we
collected several sets of elliptically excised keloid lesions with
2- to 4-mm peripheral borders of clinically normal skin from
the same patient and carried out tissue homogenate lysates for
western blot analyses. Results of three representative sets of
keloid lesions and their associated clinically normal skin borders
showed a consistent two- to three-fold increase in PAI-1 protein
level in keloid tissues compared with their own control normal
skins (Fig 1A). Elevated PAI-1 mRNA expression was also
demonstrated by northern blot analyses in primary cultured
keloid ¢broblasts derived directly from the same tissue samples
(Fig 1B). The consistent ¢ndings of elevated PAI-1 in both
tissues and tissue-derived cells con¢rm that fundamental in vivo
biologic di¡erences are recapitulated by an in vitro system. We
next examined the expression of HIF-1a protein, a well-
characterized biomarker for tissue hypoxia (Shabsigh et al, 2001),
using the same sets of tissue homogenate lysates. Western blot
analyses (Fig 1A) revealed an intrinsically elevated HIF-1a
protein levels (two- to three-fold increase) in keloid tissues
compared with their clinically normal bordering skins,
suggesting that a local hypoxic state exists in keloid tissues.
PAI-1 mRNA half-life is increased in keloid ¢broblasts Next
we investigated mechanisms responsible for the elevation of PAI-1
in keloid ¢broblasts. Because other studies using nuclear runo¡
analyses have attributed the overexpression of PAI-1 in keloid
¢broblasts to the transcriptional regulation (Higgins et al, 1999), we
conducted a study on mRNA stability in keloid and normal
¢broblasts after inhibiting transcriptional activities with actino-
mycin D treatment (Fig 2). Northern blot analyses revealed that
under normoxic conditions, the 3.2-kb PAI-1 mRNA was
degraded at a much slower rate in keloid ¢broblasts (Fig 2A1) than
in normal skin ¢broblasts (Fig 2B1). Densitometric analyses of 3.2-
kb PAI-1 transcripts were graphically depicted (Fig 2C,D), and
linear regression analyses revealed a twofold increase in the half-
life for the 3.2-kb PAI-1 message in the keloid ¢broblasts (t1/
2¼ 24.31 h) compared with that in the normal cells (t1/2¼10.51 h;
po0.01) (Table II). Conceivably, the increase in PAI-1 mRNA
stability may have contributed, at least in part, to the elevated
basal PAI-1 expression in keloid ¢broblasts. Nevertheless, the
mechanisms responsible for the increase in PAI-1 mRNA half-life
in keloids remain to be elucidated.
Hypoxia increases PAI-1 mRNA half-life in primary
cultured ¢broblasts We examined the e¡ect of hypoxia on
PAI-1 mRNA expression as well as its half-life by exposing
primary cultured ¢broblasts to either environmental or
intracellular hypoxic conditions, followed by treatment with
actinomycin D (5 mg/mL). Northern blot analyses showed that
under extreme intracellular hypoxia generated by DFO, both
3.2- and 2.4-kb PAI-1 mRNA transcripts were degraded at a
much slower rate than those under normoxic condition in both
normal skin (Fig 2B2 vs. 2B1) and keloid ¢broblasts (Fig 2A2 vs.
2A1). Linear regression analyses indicated that the intracellular
hypoxic state induced by DFO increased the half-life of the
3.2-kb PAI-1 mRNA in keloid ¢broblasts to about 200%
more than the normoxic control (t1/2(DFO)¼ 52.23 h; t1/2
(normoxia)¼ 24.31 h; po0.01) (Fig 2C, Table II). Nevertheless,
a ¢vefold increase in the half-life of the 3.2-kb PAI-1 mRNA
induced by DFO was observed in normal skin ¢broblasts as
compared with that in normoxia (t1/2(DFO)¼ 52.50 h; t1/2
(normoxia)¼ 10.51 h; po0.001) (Fig 2D,Table II).
Similarly, the 3.2-kb PAI-1 mRNA degraded more slowly
under environmental hypoxia in both normal skin (Fig 2F2 vs.
2F1) and keloid ¢broblasts (Fig 2E2 vs. 2E1) than it did under
Figure1. Keloid tissues and ¢broblasts express higher levels of PAI-
1 and HIF-1a than normal skins. (A) Western blot analyses of PAI-1
and HIF-1a proteins present in tissue homogenates obtained from three re-
presentative sets of keloid lesions (K1, K2, K3) and associated clinically nor-
mal peripheral skins (N1, N2, N3); N1 and K1were obtained from the same
patient and likewise for N2, K2 or N3, K3. (B) Northern blot analyses of
PAI-1 mRNAs using dermal ¢broblasts isolated from the corresponding
keloid tissues and associated normal skin borders.
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normoxic conditions. Nevertheless, it appeared that under
environmental hypoxia, the 2.4 -kb PAI-1 transcript has a
relatively faster decay rate than that of 3.2-kb transcript in both
keloid (Fig 2E2) and normal ¢broblasts (Fig 2F2). Linear
regression analyses showed a 150% longer half-life for the 3.2-kb
PAI-1 mRNA in keloid ¢broblasts in response to environ-
mental hypoxia (t1/2(hypoxia)¼ 33.84 h; t1/2(normoxia)¼ 20.82 h;
po0.05) (Fig 2G, Table II). It is noteworthy that the enviro-
nmental hypoxia induced a threefold increase in the half-life of
the 3.2-kb PAI-1 transcript in normal skin ¢broblasts compared
with that in normoxia (t1/2(hypoxia)¼ 36.17 h; t1/2(normoxia)¼
12.64 h; po0.01) (Fig 2H, Table II). The di¡erence in PAI-1
induction between environmental versus intracellular hypoxic
conditions may be explained by a variation in O2 perfusion rate
e⁄cacy.
Cycloheximide upregulated PAI-1 mRNA expression in
keloid ¢broblasts To test whether mechanisms underlying the
Figure 2. E¡ect of hypoxia on PAI-1 mRNA stability in primary cultured dermal ¢broblasts. Northern blot analyses of PAI-1mRNA half-life of
normal skin ¢broblasts (B,F) or keloid ¢broblasts (A,E) exposed to normoxia (20% O2), intracellular hypoxia (DFO, 130 mmol/L) or environmental hypoxia
(2% O2) for 24 h. (C,D,G,H) Densitometric analyses of the 3.2-kb PAI-1mRNAs with the PAI-1mRNA/b-actin ratio at time point 0 h arbitrarily set as 1.0.
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hypoxia-induced increase in the steady-state levels of PAI-1
mRNA are dependent on de novo protein synthesis in keloid
¢broblasts, we exposed cells to intracellular or environmental
hypoxia in the presence or absence of pretreatment with CHX,
a eukaryotic protein synthesis inhibitor. Subcon£uent cultures
of keloid ¢broblasts were pretreated with CHX (10 mg/mL) for
2 h before exposure to normoxia, DFO (Fig 3), or
environmental hypoxia (Fig 4). As observed earlier, both
intracellular hypoxia (DFO) and environmental hypoxia (2%
O2) induced a two- to 3-fold increase in both 3.2- and 2.4 -kb
PAI-1 transcripts. Treatment of keloid ¢broblasts with CHX
alone caused 8- to 10-fold induction of PAI-1 mRNA levels,
especially the 3.2-kb transcript, under normoxic conditions
(Figs 3B, 4B). The huge induction e¡ect was even stronger than
those observed in either DFO or hypoxia (Figs 3, 4).
Nevertheless, no synergistic e¡ect of PAI-1 mRNA induction
was observed following a combined treatment with either DFO
or environmental hypoxia and CHX (Figs 3, 4).
Hypoxia-induced activation of human PAI-1 promoter
requires de novo protein synthesis To test whether the
upregulation of the steady-state level of PAI-1 mRNA by
hypoxia or CHX is mediated at the transcriptional level, we
transiently transfected keloid ¢broblasts with the pGL3PAI-
800Luc reporter construct followed by exposure to di¡erent
treatment conditions (Fig 5). As expected, both environmental
hypoxic (2% O2) and intracellular hypoxic conditions (DFO)
increased promoter activities severalfold, suggesting that hypoxia
treatment is capable of inducing PAI-1 promoter activity. In
contrast to the multiple fold induction of PAI-1 mRNA levels
observed in keloid ¢broblasts, CHX alone did not increase
PAI-1 promoter activity in transfected cells under normoxic
conditions. This interesting ¢nding suggests that CHX-mediated
accumulation of PAI-1 mRNA in keloid ¢broblasts may not
be regulated at the transcriptional level, but rather it may
involve other post-transcriptional regulations. Furthermore,
CHX obviously inhibited hypoxia and DFO-induced PAI-1
promoter activities (Fig 5), implying a dependence on de novo
protein synthesis in the hypoxic regulation of the increased
steady-state PAI-1 mRNA level in keloid ¢broblasts.
Actinomycin D blocked hypoxia-induced upregulation of
PAI-1 gene in keloid ¢broblasts Studies to date have shown
that regulation of PAI-1 gene expression may occur at the
transcriptional and/or post-transcriptional levels, depending on
the context of cell types and stimuli. We studied the e¡ect of
Table II. Regression analyses of PAI-1 mRNA half-lives (h)a
DFO (  ) DFO (þ ) Normoxia Hypoxia
Normal skin 10.51 (0.96273) 52.50 (0.99720)b 12.64 (0.94358) 36.17 (0.97210)b
Keloid 24.31 (0.96798)c 52.23 (0.99875)c 20.82 (0.95160)d 33.84 (0.96620)d
aNumber in parentheses is r value.
bpo0.001
cpo0.01.
dpo0.05.
Figure 3. E¡ect of cycloheximide on DFO-induction of PAI-1
mRNA expression in cultured keloid ¢broblasts. (A) Northern blot
analysis of PAI-1 mRNA following treatment with DFO or CHX. Lane
1, control; lane 2, incubation with CHX (10 mg/mL) for 26 h; lane 3, treat-
ment with DFO (130 mmol/L) for 24 h; and lane 4, following pretreatment
with CHX for 2 h, cells were further incubated with DFO for 24 h. (B)
Densitometric analysis of the 3.2-kb PAI-1 mRNAs.
Figure 4. E¡ect of cycloheximide and actinomycin D on hypoxia
upregulation of PAI-1 mRNA expressions in cultured keloid ¢bro-
blasts. (A) Northern blot analyses of PAI-1 mRNA following di¡erent
treatments. Lane 1, control; lane 2, exposure to hypoxia (2% O2) for 24 h
(hyp); lane 3, incubation with actinomycin D alone (act. D; 5 mg/mL) for 26
h; lane 4, following pretreatment with actinomycin D for 2 h, cells were
exposed to hypoxia for 24 h; lane 5, incubation with CHX (10 mg/mL)
alone for 26 h; lane 6, following pretreatment with CHX for 2 h, cells were
exposed to hypoxia for another 24 h. (B) Densitometric analysis of the
3.2-kb PAI-1 mRNAs.
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actinomycin D (5 mg/mL) on hypoxia regulation of PAI-1
mRNA expression in cultured primary keloid ¢broblasts
(Fig 4). As predicted, actinomycin D completely abolished
hypoxia-induced PAI-1 mRNA expression to the basal level
(normoxic condition) (Fig 4A, lane 4). Interestingly, the
blockage of RNA synthesis resulted in a mild increase in the
basal steady-state level of PAI-1 mRNA (Fig 4A, lane 3). These
results suggest that hypoxia-mediated increase in PAI-1
expression in keloid ¢broblasts is regulated, at least in part, at
the transcriptional level.
Depletion of HIF-1a decreases PAI-1 expression in keloid
¢broblasts Recent studies in other cell systems have
demonstrated the indispensable role of HIF-1a in hypoxia-
induced PAI-1 expression (Kietzmann et al, 1999; Fink et al,
2002). To gain insights into the role of HIF-1a in hypoxia-
induced PAI-1 gene expression in keloid ¢broblasts, we depleted
HIF-1a mRNA expression by transfecting cells with HIF-1a
antisense oligonucleotides (Fig 6). The results con¢rmed that
treatment with anti-HIF-1a oligonucleotides led to a complete
attenuation of the steady-state level of HIF-1a mRNA (Fig 6).
RT-PCR showed that PAI-1 mRNA expression was nearly
abolished following treatment with anti-HIF-1a oligonucleo-
tides (Fig 7). This result supports the involvement of HIF-1a in
mechanisms underlying hypoxia-induced elevation of PAI-1 gene
expression in keloid ¢broblasts.
DISCUSSION
Previous histologic studies have described signi¢cant microvascu-
lar occlusions (Kischer et al, 1982; Kischer, 1992), highly collage-
nous and avascular centers of keloid lesions (Appleton et al,
1996), which may contribute to a hypoxic microenvironment in
hypertrophic scars and keloids. In this study we demonstrate that
freshly biopsied keloid tissues consistently express a higher level
of HIF-1a protein, a well-characterized protein marker for tissue
hypoxia, than did their associated clinically normal skin borders
(Fig 1A), thus providing direct evidence that a local state of
hypoxia exists in keloids.
Despite several studies showing a di¡erential expression
of PAI-1 in keloid ¢broblasts compared with normal cells (Tuan
et al, 1996; Higgins et al, 1999), until now there have been no re-
ports con¢rming similar ¢ndings in vivo. This study demonstrates
that PAI-1 levels are elevated in fresh keloid tissues in vivo in
Figure 5. Hypoxia-induced activation of PAI-1 promoter is depen-
dent on de novo protein synthesis. Semicon£uent cultures of keloid
¢broblasts were transiently transfected with the pGL3PAI-800Luc con-
struct and exposed to di¡erent treatment conditions-including environ-
mental hypoxia (hyp; 2% O2), DFO (130 mmol/L), or CHX (10 mg/mL).
The relative activities of the luciferase reporter genes were assayed. Each
column represents the mean7SEM (n¼ 3) for three separate experiments.
Figure 6. Blocking of HIF-1a mRNA expression by antisense oli-
gonucleotides. (A) Keloid ¢broblasts were transfected with HIF-1a sense
(S) and antisense oligonucleotides (AS), exposed to normoxia or hypoxia
for 48 h, and total RNAs were extracted for determination of HIF-1a and
a-actin expression by RT-PCR. (B) Ratio of HIF-1a to a-actin band den-
sities of PCR products. The result is representative of three independent
experiments.
Figure 7. E¡ect of HIF-1a depletion on PAI-1 gene expression in
keloid ¢broblasts. (A) The HIF-1a sense (S) and antisense (AS) trans-
fected cells were exposed to normoxia or hypoxia for 48 h and total RNAs
were extracted for determination of PAI-1 and a-actin expression by RT-
PCR. (B) Ratio of PAI-1 band densities to a-actin of PCR products. The
result is representative of three independent experiments.
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comparison to the associated clinically normal skin peripheral
border from the same patient (Fig 1A). Our in vitro study further
showed a prolonged half-life of basal PAI-1 messages in keloid
¢broblasts than their associated normal counterparts (Table II).
The prolonged half-life of PAI-1 messages in keloid ¢broblasts,
together with an elevation of HIF-1a protein level as observed
in vivo, would have, at least partially, contributed to an increase
in the basal levels of PAI-1 mRNA in keloid ¢broblasts (Fig 1B)
as well as an increase in the PAI-1 protein expression in keloid
tissues (Fig 1A).
The mechanisms underlying hypoxia-mediated induction of
PAI-1 mRNA expression are controversial. Uchiyama et al
(2000) reported that the half-life of PAI-1 mRNA in bovine aor-
tic endothelial cells was not a¡ected by hypoxia. Kietzmann et al
(1999) demonstrated that mild hypoxia (8% O2) induced PAI-1
gene expression in cultured rat hepatocytes directly through a
speci¢c promoter region harboring hypoxia response element-1
(175/168) and hypoxia response element-2 (165/158). Stu-
dies by Pinsky and colleagues (1998) have demonstrated that the
hypoxia-mediated induction of PAI-1 transcript resulted from an
increase in both de novo transcription as well as mRNA stability.
In our study, a 150%^200% longer half-life of the 3.2-kb PAI-1
mRNA in keloid ¢broblasts was observed under intracellular
(DFO) and environmental hypoxia (2% O2) compared with nor-
moxic conditions (Fig 2A,E;Table II). These results suggest that
hypoxia upregulates PAI-1 gene expression in keloid ¢broblasts,
at least in part, by a post-transcriptional mechanism to increase
the half-life of the 3.2-kb PAI-1 message.
Previous studies showed that following CHX treatment, no
further increase in PAI-1 mRNA expression was observed under
mild hypoxia in endothelial cells (Kietzmann et al, 1999) or in he-
patocytes infected with Rickettsia rickettsii (Shi et al, 2000). In our
system no additive e¡ects on PAI-1 mRNA induction were ob-
served in ¢broblasts pretreated with CHX, followed by exposure
to either DFO or environmental hypoxia (Figs 3, 4).These results
indicate that CHX treatment eliminates hypoxia- or DFO-in-
duced PAI-1 promoter activities (Fig 5), possibly by inhibiting
host de novo protein synthesis essential for hypoxia-induced in-
crease in steady-state levels of PAI-1mRNA in keloid ¢broblasts.
Additionally, our current studies showed that hypoxia and DFO
increased PAI-1 promoter activities by severalfold (Fig 5), and ac-
tinomycin D almost completely abolished hypoxia-induced PAI-
1 mRNA expression (Fig 4). Together, these results imply that
hypoxia also upregulates PAI-1 gene expression by activating its
transcription activities in keloid ¢broblasts.
As reported previously, treatment with CHX led to an in-
creased steady-state level of mRNA species in various cell types
(Thorens et al, 1987; Kietzmann et al, 1999; Shi et al, 2000), via a
decline in the synthesis of mRNA degredative enzymes (Scarpati
and Sadler, 1989;Yamamoto and Saito, 1998), or the presence of an
AU-rich region in the 30 -untranslated region of the mRNA spe-
cies (Shaw and Kamen, 1986). Consistent with this hypothesis,
CHX alone brought about increased levels of the 3.2-kb PAI-1
mRNA transcript in endothelial cells which, unlike the 2.4 -kb
transcript, contains such an AU-rich region (Crossman et al,
1990). Shetty and Idell (2000) reported a newly identi¢ed 60-
kDa PAI-1mRNA-binding protein that interacts with the 30 -un-
translanted region of PAI-1 mRNA to destabilize PAI-1 mRNA.
From the results reported herein, we demonstrated that CHX
also signi¢cantly increased PAI-1 mRNA, especially the 3.2-kb
transcript, in ¢broblasts derived from keloid tissues and that its
induction e¡ect was even stronger than either DFO or hypoxia
(Figs 3, 4). Moreover, CHX did not increase PAI-1 promoter ac-
tivity under normoxic conditions, suggesting that the mechan-
isms of CHX-ampli¢ed PAI-1 mRNA transcripts do not
involve the PAI-1 promoter regulation but rather involve other
mechanisms, such as regulation at the 30 -untranlslated region of
the gene.
HIF-1a is the master transcriptional factor in regulating the
expression of more than 40 target genes in response to hypoxia
(Semenza, 2002). Recent studies have demonstrated special HIF-
1a-binding sequences in the region of the PAI-1 promoter
(Kietzmann et al, 1999; Fink et al, 2002). By transfecting keloid
¢broblasts with HIF-1a antisense oligonucleotides, we were able
to attenuate HIF-1amRNA steady-state levels, leading to a sig-
ni¢cant downregulation of PAI-1 mRNA (Fig 7). This result
further supports the involvement of HIF-1a in hypoxia-induced
PAI-1 gene expression in keloid ¢broblasts.
Moreover, numerous studies revealed an abundant accumula-
tion of growth factors and cytokines in keloids (Xue et al, 2000;
Akimoto et al, 1999; Lee et al, 1999), some of which can be upre-
gulated by hypoxia (Semenza, 2002). In addition to hypoxia, PAI-
1 mRNA expression can be regulated by various growth factors,
hormones, and cytokines under normoxic conditions (Sawdey
and Loskuto¡, 1991; Fattal et al, 1992; Takeda et al, 2001). Most
recently, studies have demonstrated that, in contrast to regulation
via the ubiquitin proteasome pathway, certain translation regula-
tory proteins that are substrates of the PI3K-AKT-FRAP/mTOR
cascade can be activated by a variety of growth factors and cyto-
kines to induce HIF-1a accumulation and target gene expression
(Stiehl et al, 2002; Semenza 2002; Huang and Bunn, 2003). Taken
together, we propose that a complicated network does exist
whereby multiple pathways may have cooperatively contributed
to the regulation of the overall elevation of PAI-1 gene expression
in keloids. Therefore, it is of great importance to determine to
which extent hypoxia is signi¢cant for the observed overexpres-
sion of PAI-1 in keloids and to what extent local growth factors
and cytokines have contributed to this PAI-1 elevation.
In conclusion, this study showed that keloid tissues intrinsi-
cally express a higher level of PAI-1 protein than their associated
normal skin counterparts, which may be partially attributed to a
relatively longer half-life of the PAI-1 mRNA in keloid ¢bro-
blasts observed in vitro or/and to an elevated expression of HIF-
1a protein observed in vivo. Our study also demonstrated that
both intracellular hypoxia (DFO) and environmental hypoxia
(2% O2) resulted in a signi¢cant increase in the steady-state levels
of PAI-1mRNA.The mechanisms appear to be via an increase in
the stability of PAI-1 mRNA transcripts as well as in the promo-
ter activities in keloid ¢broblasts. Blockade of HIF-1a expression
leads to a signi¢cant suppression of hypoxia-mediated PAI-1 gene
activation. Further studies to delineate the precise signaling cas-
cades and transcriptional factor activation involved in hypoxia
versus cytokine-mediated PAI-1 gene expression will provide
valuable insights into mechanisms governing altered PAI-1
expression in keloid ¢broblasts. Understanding the mechanisms
that underlie PAI-1 regulation may contribute to future therapeu-
tic approaches for alleviating ¢brotic scarring or treating diseases
associated with altered ECM metabolism.
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